Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?
Plus
24
Ṁ12552026
30%
chance
1D
1W
1M
ALL
Since the first FDA approval for weight loss, GLP-1 receptor agonists are in the news as new blockbuster drugs.
As of today, neither Novo Nordisk's Ozempic / Wegovy (Semaglutid), nor Eli Lilly's Mounjaro / Tirzepatid are projected to generate more 2023 sales than Merck's Keytruda (Pembrolizumab, a checkpoint inhibitor used in tumor therapy).
This market will resolve YES if a GLP-1 agonist is the best-selling drug in 2025 (new sales) per reliable company or media reports.
This question is managed and resolved by Manifold.
Get
1,000and
3.00
1,0003.00Sort by:
Does it count if the drug hits multiple targets and one of the targets is GLP-1R agonism? For example, tirzepatide targets both the GLP-1 and GIP receptors.
Related questions
Related questions
Will a clinical trial reporting weight-loss benefits of a GLP-1 agonist be published in a major medical journal in 2024?
84% chance
Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027
75% chance
Reliable Reporting indicating that more than 3% of Americans are taking GLP-1 agonists in 2024
36% chance
Will a GLP-1 receptor agonist (Ozempic-like drug) be added to public water supplies in the United States by 2075?
30% chance
Will Donald Trump ever take a GLP-1 agonist (eg Ozempic, Mounjaro, Wegovy, Zepbound, etc) for weight loss
65% chance
What fraction of US adults will regularly take GLP-1 drugs in 2030?
Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by 01/01/2025?
12% chance
Will Ozempic/GLP-1 Agonists become an issue with a clear partisan divide in the US in the next 5 years?
38% chance
Affordable weight loss drugs before 2030?
67% chance
Will one of the GLP agonist drugs (eg Semaglutude/Wegovy Tirzepatide/Mounjaro) have a black box warning by 2025
33% chance